Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Eur J Cancer Care (Engl). 2011 May;20(3):287-93. doi: 10.1111/j.1365-2354.2010.01224.x. Epub 2010 Sep 6.
Surgical cytoreduction and platinum/taxane combination chemotherapy are the mainstay for the treatment of epithelial ovarian cancer patients. In order to minimise the tumour mass before chemotherapy, cytoreductive surgery is usually performed first. Currently, a splenectomy is included as part of surgical cytoreduction in epithelial ovarian cancer, but it is rarely performed. A splenectomy is also performed as part of secondary cytoreduction surgery. Although there are many reports on surgical techniques, safety and associated clinical outcomes of a splenectomy as a standard adjunct of ovarian cytoreductive surgery, most evidence is from case(s) reports, with only a few studies. Thus, we conducted a review of the literature on this unusual procedure in the context of primary and secondary cytoreduction of epithelial ovarian cancer to assess the published evidence for its efficacy and safety.
手术细胞减灭术和铂类/紫杉类联合化疗是上皮性卵巢癌患者治疗的主要方法。为了在化疗前使肿瘤体积最小化,通常首先进行细胞减灭术。目前,在卵巢上皮性癌的细胞减灭术中包括脾切除术,但很少进行。脾切除术也是二次细胞减灭术的一部分。尽管有许多关于手术技术的报道,但脾切除术作为卵巢细胞减灭术标准辅助手段的安全性和相关临床结局,大多数证据来自病例报告,仅有少数研究。因此,我们对上皮性卵巢癌初次和二次细胞减灭术中脾切除术的相关文献进行了回顾,以评估其疗效和安全性的现有证据。